Samsung finalizes Raypax beta site

Article

Samsung finalizes Raypax beta siteKorean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax

Samsung finalizes Raypax beta site

Korean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax since it received 510(k) clearance earlier this year (

PNN

8/99). The system was installed the first week of August, and initially will deal with two modalities, CT and MRI. Samsung, which maintains U.S. operations in San Jose, CA, will work with PAMC to create a version of Raypax that meets the requirements of American radiologists, the company said.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.